Valtech has a specialized team to perform regular market and valuation research to provide valuable insights to our exclusive clients

Biotech Valuation & Healthcare Valuation Service

By |2021-05-14T05:13:55+00:00May 10th, 2021|Categories: Business Valuation, Valtech Insights|Tags: , , , , |

Given the uncertainties associated with valuation of biotech enterprises, valuers can put stronger effort in benchmarking. A solid pool of comparable listed companies and comparable transaction will be highly useful to support valuation assumptions at different clinical trial phase.

ESG and Business Valuation

By |2021-04-01T09:16:48+00:00April 1st, 2021|Categories: Business Valuation, News, Valtech Insights|

Why Consider ESG in Valuation? Different environmental disasters, social unrest and the governance amid COVID-19 makes ESG reports more important to value a company. In order to increase comparability of ESG reports, different institutions include the IFRS foundation, the CFA Institute and the EFRAG are now considering to develop a global reporting standard for

Capital Structure Considerations in Business Valuation

By |2021-05-10T07:03:06+00:00May 29th, 2020|Categories: Business Valuation, News, Valtech Insights|Tags: , |

The latest 2020 edition of the International Valuation Standards (IVS) marks an important milestone towards harmonising valuation practice worldwide. Valtech has been closely following the development of IVS. IVS is applicable in many of our valuation engagements looking for consistency and transparency for potential investment decisions.

Expected Credit Loss Assessment

By |2020-03-25T17:19:34+00:00March 25th, 2020|Categories: Financial Instruments, Financial Reporting IFRS HKFRS, Valtech Insights|Tags: , |

Many companies still struggle in how to fulfill the requirement to consider forward looking information in the expected credit loss adjustment. Let’s recall the standard’s requirement on this matter.

Go to Top